Effects of the addition of gemcitabine,and paclitaxel-first sequencing,in neoadjuvant sequential epirubicin,cyclophosphamide, and paclitaxel for women with high-risk early breast cancer (Neo-tAnGo): an open-label, 2×2 factorial randomised phase 3 trial |